APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for 35-42 days (n = 3,759) versus subcutaneous enoxaparin for 10 days (n = 3,754). (p = 0.054) Results Asymptomatic proximal deep-vein thrombosis or symptomatic venous thromboembolism: 6.9% of the betrixaban group versus 8.5% of the enoxaparin group (p = 0.054) Major bleeding: 0.7% versus 0.6% (p = 0.55), respectively, for betrixaban versus enoxaparin 8.5 % 6.9 Conclusions Among patients hospitalized with an acute medical illness, extended-duration betrixaban was not superior to short-duration enoxaparin in preventing thrombotic complications Bleeding was similar between the groups Betrixaban Enoxaparin Cohen AT, et al. N Engl J Med 2016;375:534-44